These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4. Lennon D Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051 [No Abstract] [Full Text] [Related]
5. The challenge of post-implementation surveillance for novel meningococcal vaccines. Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578 [TBL] [Abstract][Full Text] [Related]
6. Meningococcal serogroup B outbreaks and use of 4CMenB vaccine. Rose WE J Am Pharm Assoc (2003); 2014; 54(2):198-201. PubMed ID: 24632933 [No Abstract] [Full Text] [Related]
7. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci. Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907 [TBL] [Abstract][Full Text] [Related]
8. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Martin NG; Snape MD Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957 [TBL] [Abstract][Full Text] [Related]
9. Pfizer’s men B vaccine shows promise in phase 2. Hum Vaccin Immunother; 2012 Aug; 8(8):1016-7. PubMed ID: 23359878 [No Abstract] [Full Text] [Related]
10. [Meningococcal vaccines: from polysaccharide to conjugate vaccines]. Cohen R; Levy C Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368 [TBL] [Abstract][Full Text] [Related]
11. A new meningococcal B vaccine for adolescents and adults: characteristics and methods of use. Azzari C; Bonanni P J Prev Med Hyg; 2018 Dec; 59(4):E257-E260. PubMed ID: 30656227 [TBL] [Abstract][Full Text] [Related]
12. Development of a vaccine against serogroup B has been the main scientific challenge. Preface. Rappuoli R; Pizza M; Black S; Moxon ER Vaccine; 2012 May; 30 Suppl 2():B1-2. PubMed ID: 22607893 [No Abstract] [Full Text] [Related]
13. Recent developments in vaccines to prevent meningococcal serogroup B infections. Vermont CL; van den Dobbelsteen GP; de Groot R Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468 [TBL] [Abstract][Full Text] [Related]
14. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis. Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398 [TBL] [Abstract][Full Text] [Related]
15. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053 [TBL] [Abstract][Full Text] [Related]
16. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. Andrews SM; Pollard AJ Lancet Infect Dis; 2014 May; 14(5):426-34. PubMed ID: 24679664 [TBL] [Abstract][Full Text] [Related]
18. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MacNeil JR; Rubin L; Folaranmi T; Ortega-Sanchez IR; Patel M; Martin SW MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(41):1171-6. PubMed ID: 26492381 [TBL] [Abstract][Full Text] [Related]
19. Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact. Wassil J; Huels J; Narasimhan V Vaccine; 2014 May; 32(25):2943. PubMed ID: 23962533 [No Abstract] [Full Text] [Related]
20. [Bexsero, a novel vaccine against meningococcus]. Lakos A; Torzsa P; Ferenci T Orv Hetil; 2016 Feb; 157(7):242-6. PubMed ID: 26853725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]